



GP 1614  
#5  
3.8  
PATENT 425-01

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : John D. Nelson et al.  
Serial No. : 09/599,371  
Filed : June 22, 2000  
For : PYRITHIONE BIOCIDES ENHANCED BY  
SILVER, COPPER, OR ZINC IONS  
Examiner :  
Attorney Docket : 101992-200  
Group Art Unit : 1614

RECEIVED

NOV 20 2000

TECH CENTER 1600/2900

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an  
envelope addressed to: Commissioner for Patents, Washington, D.C.  
20231 on 13 Nov 2000.

By

Todd E. Garabedian  
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicant(s)

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully  
requested to consider the references cited on attached Form PTO-  
1449. A copy of each reference (if not previously submitted) is  
enclosed. It is respectfully requested that the information be  
expressly considered during the prosecution of this application,  
and that the reference(s) be made of record therein and appear  
among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed  
within three months of the U.S. filing date OR before the  
mailing date of a first Office Action on the merits. No  
certification or fee is required.
- [ ] 2. This Information Disclosure Statement is being filed  
more than three months after the U.S. filing date AND after  
the mailing date of the first Office Action on the merits,  
but before the mailing date of a Final Rejection or Notice  
of Allowance.

- [ ] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- [ ] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- [ ] Please charge Deposit Account No. **23-1665** in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- [ ] A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [ ] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
  - [ ] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
  - [ ] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
  - [ ] Please charge Deposit Account No. **23-1665** in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.

[ ] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).


The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

JOHN D. NELSON ET AL.

By

  
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicant(s)

WIGGIN & DANA  
One Century Tower  
New Haven, CT 06508

Tel.: (203) 498-4400  
Fax: (203) 782-2889

Date: 13 Nov 2000



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 20 2000

TECH CENTER 1600/2900

In re Application : John D. Nelson et al.  
 Serial No. : 09/599,371  
 Filed : Jun 2000  
 For : PYKONE BIOCIDES ENHANCED BY SILVER, COPPER, OR ZINC IONS  
 Examiner :  
 Attorney Docket : 101992-200  
 Group Art Unit : 1614

\*\*\*\*\*  
 I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on 13 Nov 2000.

By

*Todd E. Garabedian*

Todd E. Garabedian, Ph.D.

Registration No. 39,197

Attorney for Applicant(s)

\*\*\*\*\*

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE LETTER

Commissioner for Patents  
 Washington, D.C. 20231

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).


1. U.S. Patent No. 3,852,441 issued December 3, 1974 to John A. Kooistra.
2. U.S. Patent No. 5,227,156 issued July 13, 1993 to Robert S. Wiese.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

JOHN D. NELSON ET AL.

By

  
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicant(s)

WIGGIN & DANA  
One Century Tower  
New Haven, CT 06508

Telephone: (203) 498-4400  
Fax: (203) 782-2889

Date: 13 Nov 2000